Full Year
AYTU — FY2026 Annual Financial Report Analysis
Aytu's fiscal 2026 revenue fell 13.3% to $57.6M: $6.6M of revenue from its new antidepressant EXXUA did not make up for a $15.4M drop in its older ADHD and pediatric drugs, and the operating loss widened to $8.3M even though last year's $10.4M of impairment and restructuring charges did not recur.